Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research note published on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Trevena in a research note on Thursday, November 14th.

Trevena Price Performance

Shares of Trevena stock opened at $1.64 on Friday. The firm has a market cap of $1.42 million, a PE ratio of -0.03 and a beta of 1.08. Trevena has a 1 year low of $1.13 and a 1 year high of $17.50. The stock has a fifty day moving average price of $1.73 and a 200-day moving average price of $2.50.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.